Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
Carmen Criscitiello, Giulia Viale, Giuseppe Curigliano, Aron Goldhirsch European Institute of Oncology, Milano, Italy Abstract: Alteration of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin signaling pathway is key for the growth and survival of...
Enregistré dans:
Auteurs principaux: | Criscitiello C, Viale G, Curigliano G, Goldhirsch A |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2018
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/d5bcc36067914069a34e9071aacf3d50 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date [Corrigendum]
par: Criscitiello C, et autres
Publié: (2018) -
Cryoablation In The Management Of Breast Cancer: Evidence To Date
par: Pusceddu C, et autres
Publié: (2019) -
The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review
par: Irina V. Poddubnaya, et autres
Publié: (2021) -
Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
par: Armaghani AJ, et autres
Publié: (2020) -
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
par: Editorial Board
Publié: (2021)